Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BON-106 in Advanced or Metastatic Solid Tumors
NCT07893535Phase 1Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
Phase 1, open-label trial of BON-106 in solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Dose-limiting Toxicities at 1 month, Adverse Events at 24 months and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BON-106
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07893535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893535.